154 related articles for article (PubMed ID: 38190579)
21. [Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Qiu MZ; Teng KY; Ruan DY; Li YH; Chen XQ; Pan ZZ; He YJ; Wan DS; Xu RH
Ai Zheng; 2009 Jul; 28(7):743-8. PubMed ID: 19624903
[TBL] [Abstract][Full Text] [Related]
22. Increasing tumor budding in cholangiocarcinoma is associated with decreased disease-specific survival.
Agostini-Vulaj D; Cates JMM; Bratton LE; Gonzalez RS
Hum Pathol; 2021 May; 111():75-83. PubMed ID: 33727168
[TBL] [Abstract][Full Text] [Related]
23. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
[TBL] [Abstract][Full Text] [Related]
24. Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer.
Akabane S; Shimizu W; Takakura Y; Kochi M; Taguchi K; Nakashima I; Sato K; Hattori M; Egi H; Sentani K; Yasui W; Ohdan H
Int J Clin Oncol; 2021 Jul; 26(7):1285-1292. PubMed ID: 33881678
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant chemotherapy in stage II and III colon cancer: the role of the "budding and TILs-(tumor-infiltrating lymphocytes) combination" as tumor-host antagonists.
Lang-Schwarz C; Melcher B; Dregelies T; Norouzzadeh Z; Rund-Küffner S; Lang-Schwarz K; Vieth M; Sterlacci W
Int J Colorectal Dis; 2021 Aug; 36(8):1765-1779. PubMed ID: 33745027
[TBL] [Abstract][Full Text] [Related]
26. Differential clinical impacts of tumour budding evaluated by the use of immunohistochemical and haematoxylin and eosin staining in stage II colorectal cancer.
Yamadera M; Shinto E; Kajiwara Y; Mochizuki S; Okamoto K; Shimazaki H; Hase K; Ueno H
Histopathology; 2019 Jun; 74(7):1005-1013. PubMed ID: 30698857
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases.
Capussotti L; Muratore A; Mulas MM; Massucco P; Aglietta M
Br J Surg; 2006 Aug; 93(8):1001-6. PubMed ID: 16739103
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age.
Liang JT; Huang KC; Cheng AL; Jeng YM; Wu MS; Wang SM
Br J Surg; 2003 Feb; 90(2):205-14. PubMed ID: 12555297
[TBL] [Abstract][Full Text] [Related]
29. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases.
Figueras J; Valls C; Rafecas A; Fabregat J; Ramos E; Jaurrieta E
Br J Surg; 2001 Jul; 88(7):980-5. PubMed ID: 11442531
[TBL] [Abstract][Full Text] [Related]
30. Tumour deposits in colon cancer predict recurrence and reduced survival in a nationwide population-based study.
Jörgren F; Agger E; Lydrup ML; Buchwald P
BJS Open; 2023 Nov; 7(6):. PubMed ID: 38035752
[TBL] [Abstract][Full Text] [Related]
31. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
32. Optimal use of adjuvant chemotherapy in stage II colorectal cancer.
Zhou Z; Wu X; Wang R; Li L; Lu Z; Chen G; Fang Y; Pan Z
Int J Colorectal Dis; 2011 Jul; 26(7):867-73. PubMed ID: 21431851
[TBL] [Abstract][Full Text] [Related]
33. The prognostic influence of tumour budding in Western patients with stage II colorectal cancer.
Canguçu AL; Valério E; Peixoto RBP; Felismino TC; de Mello CAL; Neotti T; Calsavara VF; de Macedo MP; Júnior SA; Riechelmann R
Ecancermedicalscience; 2020; 14():1130. PubMed ID: 33209121
[TBL] [Abstract][Full Text] [Related]
34. Tumour budding at invasive margins and outcome in colorectal cancer.
Kanazawa H; Mitomi H; Nishiyama Y; Kishimoto I; Fukui N; Nakamura T; Watanabe M
Colorectal Dis; 2008 Jan; 10(1):41-7. PubMed ID: 18078460
[TBL] [Abstract][Full Text] [Related]
35. Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer.
Garfinkle R; Lee L; Boutros M; Cardin MJ; Spatz A; Morin N
Can J Surg; 2019 Oct; 62(5):334-339. PubMed ID: 31550095
[TBL] [Abstract][Full Text] [Related]
36. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases.
Laurent C; Sa Cunha A; Couderc P; Rullier E; Saric J
Br J Surg; 2003 Sep; 90(9):1131-6. PubMed ID: 12945082
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.
Tanis E; Julié C; Emile JF; Mauer M; Nordlinger B; Aust D; Roth A; Lutz MP; Gruenberger T; Wrba F; Sorbye H; Bechstein W; Schlag P; Fisseler A; Ruers T
Eur J Cancer; 2015 Nov; 51(17):2708-17. PubMed ID: 26342674
[TBL] [Abstract][Full Text] [Related]
38. Multicentre study of perioperative
Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
[TBL] [Abstract][Full Text] [Related]
40. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
